2015
The Lifetime Medical Cost Savings From Preventing HIV in the United States
Schackman BR, Fleishman JA, Su AE, Berkowitz BK, Moore RD, Walensky RP, Becker JE, Voss C, Paltiel AD, Weinstein MC, Freedberg KA, Gebo KA, Losina E. The Lifetime Medical Cost Savings From Preventing HIV in the United States. Medical Care 2015, 53: 293-301. PMID: 25710311, PMCID: PMC4359630, DOI: 10.1097/mlr.0000000000000308.Peer-Reviewed Original ResearchConceptsHIV infectionLifetime medical costsMedical costsUS health system perspectiveAntiretroviral treatment statusHIV disease treatmentHIV Research NetworkTransmission risk groupsCD4 cell countHigh-risk individualsHealth system perspectiveHIV prevention interventionsMedical cost savingsMedical Expenditure Panel SurveyLifetime cost estimatesRace/ethnicityPreexposure prophylaxisHIV diseaseHIV preventionRisk groupsPrevention interventionsAge 35High riskSecondary infectionTreatment status
2006
The Survival Benefits of AIDS Treatment in the United States
Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, Weinstein MC, Freedberg KA. The Survival Benefits of AIDS Treatment in the United States. The Journal Of Infectious Diseases 2006, 194: 11-19. PMID: 16741877, DOI: 10.1086/505147.Peer-Reviewed Original ResearchConceptsSurvival benefitAntiretroviral therapyPotent combination antiretroviral therapyPneumocystis jiroveci pneumonia prophylaxisHIV disease treatmentImmunodeficiency syndrome careOpportunistic infection prophylaxisTotal survival benefitUntreated HIV diseaseCombination antiretroviral therapyEffective antiretroviral therapyPrevention of motherAbsence of treatmentYears of lifePneumonia prophylaxisChild transmissionInfant infectionAdult patientsHIV diseaseInfection prophylaxisDisease careNew diagnosisAIDS treatmentProphylaxisSurvival increase